BRSYF (BrainsWay) Valuation Rank


BRSYF BrainsWay Ltd BRSYF
70 GF Score
Price $13.55
GF Value $6.24
! 6 Warning Signs
View Full Analysis

What is BrainsWay Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BrainsWay Valuation Rank Related Terms

BRSYF
70GF Score
BrainsWay Ltd BRSYF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BrainsWay (BRSYF) Overvalued in 2026?

Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued. The current stock price of $13.55 is trading 117.1% above its estimated GF Value™ of $6.24.

Key valuation signals for BRSYF:

  • Valuation Rank:
  • GF Value™: $6.24 vs. price of $13.55 (117.1% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the BRSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BrainsWay Business Description

Other Exchanges BWAY:USABWAY:Israel
Address 16 Hartum Street, 14th Floor, RAD Tower, Har HaHotzvim, Jerusalem, ISR, 9777516
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
70GF Score

Get the complete analysis for BRSYF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.55
Price
$6.24
GF Value